Instrument Inactif

Communiqués Coeptis Therapeutics, Inc. OTC Markets

Actions

COEP

US19207C1045

Communiqués

Coeptis Therapeutics : CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF COEPTIS THERAPEUTICS HOLDINGS, INC Form 8 K	20/06	PU
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering	20/06	PR
Coeptis Therapeutics Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting	31/05	AQ
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting	30/05	PR
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024	08/05	PR
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene and Cell Therapy 27th Annual Meeting	03/05	AQ
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on receiving the 2024 Chancellor s Distinguished Research Award	03/04	AQ
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award	02/04	PR
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	27/02	AQ
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	07/02	PR
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024	04/01	PR
Coeptis Therapeutics to Present at the Emerging Growth Conference	04/12	PR
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023	31/10/23	PR
Coeptis Therapeutics Announces $2 Million Private Placement	24/10/23	PR
Coeptis Therapeutics : Private Placement - Form 8-K	13/10/23	PU
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	11/10/23	PR
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies	09/10/23	PR
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting	04/10/23	PR
Coeptis Therapeutics to Present at the 2023 Cell and Gene Meeting on the Mesa	28/09/23	AQ
Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa	27/09/23	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Coeptis Therapeutics, Inc. OTC Markets

Actions

COEP

US19207C1045

Communiqués

Filtres